Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.69 |
| ▸ | PDE4A | P27815 | 6/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.69 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6957705 | 0.81 | PDE4D (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL6957343 | 0.80 | PDE4A (0.63) | PDE4BPDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL6955141 | 0.74 | PDE4A (0.55) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL13210698 | 0.72 | KCNMA1 (0.74) | PDE4BPDE4APDE4CPDE4DKCNMA1 | |
| SCHEMBL4702655 | 0.71 | PDE4A (1.00) | PDE4BPDE4APDE4CPDE4DKCNMA1 | |
| SCHEMBL6954801 | 0.70 | PDE4B (0.55) | PDE4BPDE4APDE4CPDE4DKCNMA1 | |
| SCHEMBL8270346 | 0.70 | PDE4A (0.64) | PDE4BPDE4APDE4CPDE4DKCNMA1 | |
| SCHEMBL6778054 | 0.69 | SMN1; SMN2 (0.78) | KCNMA1JAK2SMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL6950187 | 0.69 | PDE4A (0.58) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL6836458 | 0.68 | KCNMA1 (0.56) | PDE4BPDE4APDE4CPDE4DKCNMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | claimed |
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-07-18 | — | — | US | claimed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | claimed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | claimed |
| EP-0944616-B1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-07-18 | — | — | US | disclosed |
| US-6353010-B1 | ENZYME INHIBITORS TUMOR NECROSIS FACTOR AND PHOSPHODIESTERASE FOR ANTIINFLAMMATORY AGENTS | DARWIN DISCOVERY, LTD. (GB) | 2002-03-05 | — | — | US | disclosed |
| EP-0944616-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998022460-A1 | BICYCLIC ARYL CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094987-A1 | Bicyclic aryl carboxamides and their therapeutic use | PDE3B, PDE3A, PDE2A | PDE4B 12/4885PDE4A 9/4885PDE4C 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.